Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder

Stopped early · Not applicable

Conditions studied: Bipolar Disorder, Metabolic Syndrome

In brief

The proposed study is a non-randomized, open label trial that will examine the potential to reduce metabolic risk factors in patients with bipolar I disorder and improve psychiatric and functional outcomes. To accomplish our objective, we plan to conduct a 5-month intervention of 50 obese or overweight adults diagnosed with bipolar disorder. The study will be divided in three steps: Screening, Baseline Period (cross taper to aripiprazole, up to 2 months in duration), Months 1-3 (continued aripiprazole treatment). Subjects will be assessed and meet with their study psychiatrist at least bi-monthly throughout their participation, more frequently when clinically necessary (e.g. during medication tapering or if manic/depressive symptoms emerge). Brief clinical assessments will be conducted at each visit. More thorough assessments will be conducted at Baseline, Week 2, and Month 3.

Key facts

Study ID

NCT00665444

Run by

University of Pittsburgh

People needed

3

Starts

2008-04-01

Expected to finish

2009-08-01

Last updated by the study team

2017-11-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 to 65 years
• Body mass index (BMI) >=25;
• Currently taking a regimen of medications for bipolar disorder likely to cause, sedation, weight gain or undesirable metabolic effects;
• Able to give basic informed consent
• Meets DSM-IV criteria for lifetime bipolar I or II disorder and are presently in sustained remission (CGI BP<3 in the previous 8-week period measured through a complete psychiatric history at screening and patient report.)
• Epworth Scale Score > 7
• Women of childbearing potential must agree to use a doctor-approved birth control throughout participation in the study

You may not qualify if…

• Unwilling or unable to comply with study requirements (i.e., complete forms, attend scheduled evaluations)
• Not competent to provide informed consent in the opinion of the investigator
• Ultra-rapid cycling (>4 episodes per month) bipolar I disorder
• Unstable and severe medical illness that requires immediate and intensive medical attention, When appropriate, the patients can be reconsidered for inclusion in the study if/when their medical condition becomes compatible with participation in a protocol-driven research study
• Women who are planning to become pregnant, currently pregnant, or breast-feeding;
• Current substance dependence; however, if a subject only has substance abuse/use, after the first positive drug screen, another drug screen will be repeated. If that drug screen is positive, the subject will be excluded. If the second drug screen is negative, the subject will be considered for the study;
• Subjects who have previously failed an adequate trial of aripiprazole.
• Subjects with a suicide attempt in the past 2 years;
• Subjects with a history of inpatient admission in the past 1 year;
• Subjects with a history of homicidal ideation;
• Any subject for whom the PI deems that the potential risks in participating in the study outweigh the potential benefits.

Where it is running

• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.